Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.77 |
| ▸ | CASP7 | P55210 | 3/20 | 0.77 |
| ▸ | CASP1 | P29466 | 2/20 | 0.77 |
| ▸ | CASP4 | P49662 | 2/20 | 0.77 |
| ▸ | CASP9 | P55211 | 2/20 | 0.77 |
| ▸ | CASP6 | P55212 | 2/20 | 0.77 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA9 | Q16790 | 3/20 | 0.67 |
| ▸ | ACHE | P22303 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8019897 | 0.88 | CASP3 (0.79) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL13017740 | 0.87 | ACHE (0.61) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL8019337 | 0.87 | CASP3 (1.00) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL13627912 | 0.84 | MAPT (0.57) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL16329852 | 0.83 | ACHE (0.83) | CA12CA1CA2CA9ACHE | |
| SCHEMBL28946309 | 0.83 | CASP3 (0.66) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL29699570 | 0.81 | CASP3 (0.67) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL28799594 | 0.81 | CASP3 (0.67) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL21774731 | 0.81 | CASP1 (0.67) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL18954825 | 0.80 | CA1 (1.00) | CASP3CASP7CASP1CASP4CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608369-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | CHIRON CORPORATION (US) | 2005-06-23 | — | — | US | claimed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| EP-1608369-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2258365-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2583678-A2 | Small molecule immunopotentiators and assays for their detection | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2583678-A2 | Small molecule immunopotentiators and assays for their detection | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7893096-B2 | For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893096-B2 | For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2258365-A1 | Use of organic compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20060257852-A1 | Severe acute respiratory syndrome coronavirus | CHIRON CORPORATION (US) | 2006-11-16 | — | — | US | disclosed |
| EP-1608369-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | CHIRON CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060257852-A1 | Severe acute respiratory syndrome coronavirus | SARS1, ACE2, ACE | CASP3 1534/4885CASP7 2179/4885CASP1 1387/4885 |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | ICOS, CD14, LCP2 | CASP3 3897/4885CASP7 3519/4885CASP1 3113/4885 |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | ICOS, CD14, MAVS | CASP3 3741/4885CASP7 3911/4885CASP1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.